去污染策略与机械通气患者耐药微生物血流感染:一项随机临床试验
该随机试验于2013年12月1日至2017年5月31日在13个欧洲ICU开展,纳入预计机械通气超过24小时的患者8665例。标准护理为每日2%氯己定全身洗浴和手卫生改进项目,各ICU按随机顺序接受6个月干预:2%氯己定漱口、选择性口咽去污染(SOD,含黏菌素、妥布霉素和制霉菌素的口腔糊剂)或选择性消化道去污染(SDD,相同口腔糊剂和相同抗生素的胃肠悬液),均每日4次。主要终点ICU获得性多重耐药革兰阴性菌血流感染在基线、氯己定、SOD和SDD期分别为2.1%、1.8%、1.5%和1.2%,仅SDD期绝对风险降低0.8%(95%CI 0.1%至1.6%),但调整后风险比均未达统计学显著。28天死亡率四期分别为31.9%、32.9%、32.4%和34.1%,调整后比值比均无显著差异。作者结论为在耐药中高流行ICU的机械通气患者中,三种去污染策略均未较标准护理降低主要终点。
要点
- 在13个欧洲ICU(至少5%血流感染由产超广谱β-内酰胺酶肠杆菌科引起)中,SDD期ICU获得性多重耐药革兰阴性菌血流感染绝对风险较基线降低0.8%(95%CI 0.1%至1.6%)。
- 氯己定漱口和SOD的绝对风险降低分别为0.3%(95%CI -0.6%至1.1%)和0.6%(95%CI -0.2%至1.4%),均未达统计学显著。
- 调整后风险比:氯己定1.13(95%CI 0.68-1.88)、SOD 0.89(95%CI 0.55-1.45)、SDD 0.70(95%CI 0.43-1.14),均未达统计学显著。
- 28天死亡率基线31.9%、氯己定32.9%、SOD 32.4%、SDD 34.1%,调整后比值比均无显著差异。
- 作者结论:在耐药中高流行ICU的机械通气患者中,氯己定漱口、SOD或SDD均未较标准护理降低ICU获得性多重耐药革兰阴性菌血流感染。
适用人群与场景
- 13个欧洲ICU中至少5%血流感染由产超广谱β-内酰胺酶肠杆菌科引起的ICU。
- 纳入预计机械通气超过24小时的患者,共8665例,中位年龄64.1岁,男性5561例(64.2%)。
处置流程与药物剂量
- 标准护理:每日2%氯己定全身洗浴和手卫生改进项目。
- 氯己定漱口干预:2%氯己定漱口,每日4次。
- SOD干预:含黏菌素、妥布霉素和制霉菌素的口腔糊剂,每日4次。
- SDD干预:相同口腔糊剂及含相同抗生素的胃肠悬液,每日4次。
研究设计与关键结果
- 研究类型:随机临床试验,13个欧洲ICU,8665例预计机械通气超过24小时的患者,2013年12月1日至2017年5月31日。
- 主要终点ICU获得性多重耐药革兰阴性菌血流感染:基线2.1%、氯己定1.8%、SOD 1.5%、SDD 1.2%;绝对风险降低氯己定0.3%(95%CI -0.6%至1.1%)、SOD 0.6%(95%CI -0.2%至1.4%)、SDD 0.8%(95%CI 0.1%至1.6%)。
- 调整后风险比 vs 基线:氯己定1.13(95%CI 0.68-1.88)、SOD 0.89(95%CI 0.55-1.45)、SDD 0.70(95%CI 0.43-1.14)。
- 28天粗死亡率:基线31.9%、氯己定32.9%、SOD 32.4%、SDD 34.1%;调整后比值比 vs 基线:氯己定1.07(95%CI 0.86-1.32)、SOD 1.05(95%CI 0.85-1.29)、SDD 1.03(95%CI 0.80-1.32)。
证据类型、等级与局限
- 证据类型:随机临床试验(ClinicalTrials.gov NCT02208154)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在抗菌药物耐药中高流行的ICU中,对预计机械通气超过24小时的患者,氯己定漱口、SOD或SDD未较标准护理(每日2%氯己定全身洗浴和手卫生改进项目)降低ICU获得性多重耐药革兰阴性菌血流感染,作者结论不支持以降低该感染为目的常规采用这些策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effects of chlorhexidine (CHX) mouthwash, selective oropharyngeal decontamination (SOD), and selective digestive tract decontamination (SDD) on patient outcomes in ICUs with moderate to high levels of antibiotic resistance are unknown.
OBJECTIVE: To determine associations between CHX 2%, SOD, and SDD and the occurrence of ICU-acquired bloodstream infections with multidrug-resistant gram-negative bacteria (MDRGNB) and 28-day mortality in ICUs with moderate to high levels of antibiotic resistance.
DESIGN, SETTING, AND PARTICIPANTS: Randomized trial conducted from December 1, 2013, to May 31, 2017, in 13 European ICUs where at least 5% of bloodstream infections are caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. Patients with anticipated mechanical ventilation of more than 24 hours were eligible. The final date of follow-up was September 20, 2017.
INTERVENTIONS: Standard care was daily CHX 2% body washings and a hand hygiene improvement program. Following a baseline period from 6 to 14 months, each ICU was assigned in random order to 3 separate 6-month intervention periods with either CHX 2% mouthwash, SOD (mouthpaste with colistin, tobramycin, and nystatin), or SDD (the same mouthpaste and gastrointestinal suspension with the same antibiotics), all applied 4 times daily.
MAIN OUTCOMES AND MEASURES: The occurrence of ICU-acquired bloodstream infection with MDRGNB (primary outcome) and 28-day mortality (secondary outcome) during each intervention period compared with the baseline period.
RESULTS: A total of 8665 patients (median age, 64.1 years; 5561 men [64.2%]) were included in the study (2251, 2108, 2224, and 2082 in the baseline, CHX, SOD, and SDD periods, respectively). ICU-acquired bloodstream infection with MDRGNB occurred among 144 patients (154 episodes) in 2.1%, 1.8%, 1.5%, and 1.2% of included patients during the baseline, CHX, SOD, and SDD periods, respectively. Absolute risk reductions were 0.3% (95% CI, -0.6% to 1.1%), 0.6% (95% CI, -0.2% to 1.4%), and 0.8% (95% CI, 0.1% to 1.6%) for CHX, SOD, and SDD, respectively, compared with baseline. Adjusted hazard ratios were 1.13 (95% CI, 0.68-1.88), 0.89 (95% CI, 0.55-1.45), and 0.70 (95% CI, 0.43-1.14) during the CHX, SOD, and SDD periods, respectively, vs baseline. Crude mortality risks on day 28 were 31.9%, 32.9%, 32.4%, and 34.1% during the baseline, CHX, SOD, and SDD periods, respectively. Adjusted odds ratios for 28-day mortality were 1.07 (95% CI, 0.86-1.32), 1.05 (95% CI, 0.85-1.29), and 1.03 (95% CI, 0.80-1.32) for CHX, SOD, and SDD, respectively, vs baseline.
CONCLUSIONS AND RELEVANCE: Among patients receiving mechanical ventilation in ICUs with moderate to high antibiotic resistance prevalence, use of CHX mouthwash, SOD, or SDD was not associated with reductions in ICU-acquired bloodstream infections caused by MDRGNB compared with standard care.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02208154.
参考来源
- Wittekamp BH, Plantinga NL, Cooper BS, et al. Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial. JAMA. 2018. PMID: 30347072. doi:10.1001/jama.2018.13765
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。